Diabetes and Its Complications: Strategies to Advance Therapy and Optimize R&D

By Allan B. Haberman, PhD
 

Insight Pharma Reports – Diabetes Survey – January 2007

Please classify your organization.

Please describe the product area(s) that best describes your organization's major involvement with diabetes.

Has the level of your involvement in diabetes R&D (i.e. the product areas listed in question 2) changed over the past 4 years?

If your involvement has increased in what aspect of diabetes or its complications?

How many drugs for type 2 diabetes do you expect to launch in 2007 or 2008?

How many drugs for type 2 diabetes do you have in the pipeline (preclinical to preregistration)?

How many drugs for diabetic complications do you have in the pipeline (preclinical to preregistration)?

Do you have any pipeline drugs for obesity? If so how many?

Do you agree that the difficulty in developing safe and effective antiobesity drugs is an important barrier to successful treatment of type 2 diabetes?

Do you agree that lack of scientific knowledge of diabetes/metabolic disease is an important bottleneck to development of drugs for type 2 diabetes?

Do you have any pipeline drugs that address the following aspects of type 2 diabetes?

Do you have any pipeline drugs for the following diabetic complications?

Are you involved in the discovery of novel biomarkers for any of the following?

How important are novel biomarkers in design of your clinical trials for antidiabetic drugs?

How important is R&D collaboration to your organization's business plan in diabetes?

If collaboration is important which of the following best describes the primary mode of collaboration on which your organization relies?

Do you agree that dipeptidyl peptidase-IV inhibitors such as Merck's Januvia (sitagliptin) and Novartis's Galvus (vildagliptin) are likely to largely replace thiazolidinediones (Actos and Avandia) and sulfonylureas over the next 5-10 years?